The association of lymph node yield and survival after neoadjuvant immunotherapy for head and neck cancer: An NCDB analysis. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...
The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in ...
Adjuvant cemiplimab became a category 1 preferred option after surgery and adjuvant RT for extremely high-risk nodal or nonnodal CSCC, supported by C-POST disease-free survival benefit. Extremely high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results